Zhejiang Starry Pharmaceutical Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zhejiang Starry Pharmaceutical Co., Ltd - overview
Established
1997
Location
-, Zhejiang, China
Primary Industry
Pharmaceuticals
About
Established in 1997 and based in Xianjju, China, Zhejiang Starry Pharmaceutical Co. , Ltd operates as a contrast agent and API developer. The company's product iohexol products passed GMP certification for the first time and obtained GMP certificate in 2005. The company listed on the Shanghai Stock Exchange in March 2013 with the stock code 603520.
The company acquired Zhejiang Taizhou Haishen Pharmaceutical Co. , Ltd in 2018. The company provides generic contrast agent products. The business of the company includes R&D, production and sales of X-CT non-ionic contrast agent series and quinolone series APIs and intermediates.
The company's product includes contrast agent series and fluoroquinolone series. Contrast agent series includes iohexol, iodomeprazole and gadolinium besmeglumine. Fluoroquinolone series includes levofloxacin, levofloxacin hydrochloride and levofloxacin epoxide. The company generates revenue through the sales of healthcare products.
Current Investors
ICBC Credit Suisse Asset Management, GF Fund Management, Shenzhen Qianhai Guotai Funds
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.starrypharm.com/
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Zhejiang Starry Pharmaceutical Co., Ltd - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Announced | Jiangsu Ruishi Pharmaceutical Co., Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.